- Home
- Publications
- Publication Search
- Publication Details
Title
SGLT2i: beyond the glucose-lowering effect
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 19, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-06-27
DOI
10.1186/s12933-020-01071-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Metformin and cardiorenal outcomes in diabetes: A reappraisal
- (2020) John R. Petrie et al. DIABETES OBESITY & METABOLISM
- Efficacy and tolerability of sodium‐glucose co‐transporter‐2 inhibitors and glucagon‐like peptide‐1 receptor agonists: A systematic review and network meta‐analysis
- (2020) Humaira Hussein et al. DIABETES OBESITY & METABOLISM
- Can the Cardiovascular Risk Reductions Observed with Empagliflozin in the EMPA‐REG OUTCOME Trial be Explained by Concomitant Changes Seen in Conventional Cardiovascular Risk Factor Levels?
- (2020) Ruth L. Coleman et al. DIABETES OBESITY & METABOLISM
- Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
- (2020) Thomas A. Zelniker et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Effects of dapagliflozin in DAPA-HF according to background heart failure therapy
- (2020) Kieran F Docherty et al. EUROPEAN HEART JOURNAL
- Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes
- (2020) Mark C. Petrie et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Control of 24-hour blood pressure with SGLT2 inhibitors to prevent cardiovascular disease
- (2020) Kazuomi Kario et al. PROGRESS IN CARDIOVASCULAR DISEASES
- Prospect of Sodium–Glucose Co-transporter 2 Inhibitors Combined With Insulin for the Treatment of Type 2 Diabetes
- (2020) Yinqiu Yang et al. Frontiers in Endocrinology
- Reduction in the incidence of myocardial infarction with sodium–glucose linked cotransporter-2 inhibitors: evident and plausible
- (2019) Richard E. Gilbert et al. Cardiovascular Diabetology
- Sodium–Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease
- (2019) Radica Z. Alicic et al. DIABETES
- Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Bone Metabolism and Fracture Risk
- (2019) Yangli Ye et al. Frontiers in Pharmacology
- 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
- (2019) Donna K. Arnett et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
- (2019) Chiara Maria Assunta Cefalo et al. Cardiovascular Diabetology
- SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
- (2019) Chenguang Li et al. Cardiovascular Diabetology
- Type 2 diabetes and the kidney: Insights from cardiovascular outcome trials
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- A safety update on sodium glucose co‐transporter 2 inhibitors
- (2019) David Fitchett DIABETES OBESITY & METABOLISM
- Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
- (2019) Vlado Perkovic et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors in patients with type 2 diabetes and renal disease: overview of current evidence
- (2019) Jaime A Davidson POSTGRADUATE MEDICINE
- Canagliflozin for Japanese patients with chronic heart failure and type II diabetes
- (2019) Akira Sezai et al. Cardiovascular Diabetology
- SGLT2 Inhibitors: Nephroprotective Efficacy and Side Effects
- (2019) Carlo Garofalo et al. Medicina-Lithuania
- Diabetes Technology: Review of the 2019 American Diabetes Association Standards of Medical Care in Diabetes
- (2019) James J. Chamberlain et al. ANNALS OF INTERNAL MEDICINE
- Effects of the SGLT2 inhibitor dapagliflozin on cardiac function evaluated by impedance cardiography in patients with type 2 diabetes. Secondary analysis of a randomized placebo-controlled trial
- (2019) Benedetta Maria Bonora et al. Cardiovascular Diabetology
- Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study)
- (2019) Sho Kinguchi et al. Cardiovascular Diabetology
- Renal glucosuria is associated with lower body weight and lower rates of elevated systolic blood pressure: results of a nationwide cross-sectional study of 2.5 million adolescents
- (2019) Boris Fishman et al. Cardiovascular Diabetology
- Primary versus secondary cardiorenal prevention in type 2 diabetes: Which newer antihyperglycaemic drug matters?
- (2019) Dario Giugliano et al. DIABETES OBESITY & METABOLISM
- Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes
- (2019) Robert J. Chilton DIABETES OBESITY & METABOLISM
- Intrauterine programming of obesity and type 2 diabetes
- (2019) Denise S. Fernandez-Twinn et al. DIABETOLOGIA
- Effects of novel antidiabetes agents on apoptotic processes in diabetes and malignancy: Implications for lowering tissue damage
- (2019) Habib Yaribeygi et al. LIFE SCIENCES
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Review of Diabetes Prediction Equations in African Descent Populations
- (2019) Regine Mugeni et al. Frontiers in Endocrinology
- Renal Benefits of SGLT 2 Inhibitors and GLP-1 Receptor Agonists: Evidence Supporting a Paradigm Shift in the Medical Management of Type 2 Diabetes
- (2019) Vjera Ninčević et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- SGLT2 inhibitors and urinary tract infections
- (2019) John Wilding Nature Reviews Endocrinology
- Molecular imaging of β-cells: diabetes and beyond
- (2018) Weijun Wei et al. ADVANCED DRUG DELIVERY REVIEWS
- Risks of diabetic foot syndrome and amputation associated with sodium glucose co-transporter 2 inhibitors: A Meta-analysis of Randomized Controlled Trials
- (2018) D. Li et al. DIABETES & METABOLISM
- Development of SGLT1 and SGLT2 inhibitors
- (2018) Timo Rieg et al. DIABETOLOGIA
- SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
- (2018) Subodh Verma et al. DIABETOLOGIA
- A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity
- (2018) Motoaki Sano Journal of Cardiology
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts
- (2017) Tsung-Ming Lee et al. FREE RADICAL BIOLOGY AND MEDICINE
- Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease
- (2017) Vaibhav B. Patel et al. HEART FAILURE REVIEWS
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- SGLT2 inhibitors: are they safe?
- (2017) Sebastian Filippas-Ntekouan et al. POSTGRADUATE MEDICINE
- Effects of Sodium‐Glucose Cotransporter 2 Inhibitors on 24‐Hour Ambulatory Blood Pressure: A Systematic Review and Meta‐Analysis
- (2017) William L. Baker et al. Journal of the American Heart Association
- Effect of Sodium‐Glucose Cotransport‐2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta‐Analysis of 43 Randomized Control Trials With 22 528 Patients
- (2017) Mohsen Mazidi et al. Journal of the American Heart Association
- SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study
- (2016) Muhammad Abdul-Ghani et al. DIABETES CARE
- The effect of dapagliflozin on renal function in patients with type 2 diabetes
- (2016) Donald Elliott Kohan et al. JOURNAL OF NEPHROLOGY
- Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
- (2016) Christoph Wanner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic β -cell function and reduction of insulin resistance
- (2016) Hideaki Kaneto et al. Journal of Diabetes
- Renal effects of canagliflozin in type 2 diabetes mellitus
- (2015) Vlado Perkovic et al. CURRENT MEDICAL RESEARCH AND OPINION
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition
- (2015) Anne L. Peters et al. DIABETES CARE
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- SGLT2 inhibitor dapagliflozin promotes glucagon secretion in α islet cells
- (2015) Jennifer Sargent Nature Reviews Endocrinology
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carcinogenicity in rats of the SGLT2 inhibitor canagliflozin
- (2014) Sandra De Jonghe et al. CHEMICO-BIOLOGICAL INTERACTIONS
- A Novel Therapeutic Agent for Type 2 Diabetes Mellitus: SGLT2 Inhibitor
- (2014) Chang Hee Jung et al. Diabetes & Metabolism Journal
- Glucose transport families SLC5 and SLC50
- (2013) Ernest M. Wright MOLECULAR ASPECTS OF MEDICINE
- Long-Term Effects of Intensive Glucose Lowering on Cardiovascular Outcomes
- (2011) NEW ENGLAND JOURNAL OF MEDICINE
- Prevalence of chronic complications of type 2 diabetes mellitus in outpatients - a cross-sectional hospital based survey in urban China
- (2010) Zhaolan Liu et al. Health and Quality of Life Outcomes
- Twenty-one additional cases of familial renal glucosuria: absence of genetic heterogeneity, high prevalence of private mutations and further evidence of volume depletion
- (2008) J. Calado et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now